Sylvain Garciaz, MD, Paoli-Calmettes Institute, Marseille, France, discusses a study which compared the efficacy of venetoclax-azacitidine (ven-aza) therapy with azacitidine monotherapy in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Results demonstrated a higher overall response rate (ORR) and complete remission (CR) rate in the ven-aza group, with no excess toxicities observed. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
